Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
- Dr. Richard D. Katz Joined as Chief Financial Officer - - Raised Gross Proceeds of $50 million in Follow-on Offering - - First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in HIV - - Investor Day Scheduled for December 7, 2016 - - Third …